A Meta-Analysis of Vascular Endothelial Growth Factor for Nasopharyngeal Cancer Prognosis

Abstract

Background: Vascular endothelial growth factor (VEGF) has been reported to serve as a promising prognostic marker in several cancers. This meta-analysis aims to assess the prognostic significance of VEGF in nasopharyngeal cancer (NPC).Methods: We conducted a systematic literature search of PubMed, Embase, and the Cochrane Library for observational studies published until June, 2018 to identify observational studies on the prognostic effect of tissue VEGF expression or serum VEGF level on the survival of NPC. The primary outcome measure assessed was overall survival (OS). The secondary outcomes included disease-free survival (DFS) or progression-free survival (PFS). Summary hazard ratio (HR) and its 95% confidence interval (95% CI) were derived using a random-effects model.Results: Out of 840 retrieved citations, 16 studies inclusive of 1,345 patients were included in the analysis of tissue VEGF expression and cancer survival. The pooled HRs for OS and DFS in patients with high VEGF expression were 2.07 (95% CI: 1.32–3.25) and 5.99 (95% CI: 2.66–13.48), respectively, with significant heterogeneity between studies (I2 = 79.1% for OS and 50.2% for DFS). Tissue high VEGF expression was not significantly associated with short RFS, PFS, or MFS. Five studies also investigated the prognostic effect between serum VEGF level and patient survival and found that high serum VEGF level was significantly associated with short OS for patients with NPC (HR 2.47, 95% CI 1.16–5.28), but not with short PFS (HR 1.47, 95% CI 0.92–2.35).Conclusions: Determination of tissue VEGF expression and serum VEGF level have the potential to serve as biomarkers and add prognostic information in NPC. Prospective analyses of associated data on VEGF expression and serum VEGF level in large NPC cohorts could be further conducted to advance our understanding of the relationship between VEGF and NPC outcomes.

AMP‑activated protein kinase α1 serves a carcinogenic role via regulation of vascular endothelial growth factor expression in patients with non‑small cell lung cancer

“…Therefore, the association between VEGF and AMPK α1 levels in NSCLC were investigated. Consistent with previous reports (9,10), it was concluded that VEGF was more highly expressed in NSCLC tissues compared with adjacent non-tumor lung tissues (Fig. 2A), and higher levels of VEGF were associated with a poorer prognosis (Fig.…”

Association Between VEGF Expression and Diffusion Weighted Imaging in Several Tumors—A Systematic Review and Meta-Analysis

“…VEGF is a key factor of tumor neoangiogenesis [14]. It has been shown that overexpression of VEGF is an overall indicator of poor survival in various tumor entities emphasizing its clinical importance [40][41][42]. Therefore, it may be beneficial, when imaging can correctly predict VEGF expression of tumors enabling a non-invasive and serial approach compared to bioptic samples.…”

Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment

“…Both tumor cells and surrounding stromal cells secrete VEGF to stimulate the proliferation and survival of endothelial cells and form new blood vessels [ 7 ]. VEGF is expressed in most human cancers, and elevated VEGF expression levels are often related to a less favorable prognosis in cancer patients [ 6 , 8 ]. Bevacizumab is the first US Food & Drug Administration (FDA)-approved recombinant humanized anti-VEGF monoclonal antibody for the treatment of non-small cell lung cancer (NSCLC), metastatic breast cancer, metastatic colorectal cancer, and other solid tumors [ 9 ].…”